AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells-Reference-Cited by-同舟云学术

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

Published:2005-09-15 Issue:6 Volume:104 Page:1230-1236
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Verstovsek Srdan,Golemovic Mirna,Kantarjian Hagop,Manshouri Tashi,Estrov Zeev,Manley Paul,Sun Tong,Arlinghaus Ralph B.,Alland Leila,Dugan Margaret,Cortes Jorge,Giles Francis,Beran Miloslav

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.21299/fullpdf

Reference22 articles.

1. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

2. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

3. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

4. Targeted therapies in the treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of Cell Cycle Progression through RB Phosphorylation by Nilotinib and AT-9283 in Human Melanoma A375P Cells;International Journal of Molecular Sciences;2024-03-03

2. Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2021-09

3. Clinical Outcomes of CML Patients After Delayed Start of Nilotinib Treatment;International Journal of Hematology and Oncology;2021-03-30

4. Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR 4.5 ): The phase 2, multicenter N‐Road study;Cancer Medicine;2020-04-06

5. New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances;Hematological Oncology;2019-10-21